Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Among clinical groups, logistic model identified as good response factors, higher levels of creatinine, complement C4, total IgM, number of swollen joints, longer disease duration and complementary therapy with vitamin D, showed by odd ratio (OR) coefficients > 1.

Source: Machine Learning Algorithms Allowed the Identification of Potential Predictors of TNFi Response. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were naïve to TNFi treatment.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis

Study design awaiting verification · Frontiers in Immunology · 2021

Original publication title

Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis

Maria Luque-Tévar; Carlos Perez-Sanchez; Alejandra Mª Patiño-Trives; Nuria Barbarroja; Ivan Arias de la Rosa; Mª Carmen Abalos-Aguilera; Juan Antonio Marin-Sanz; Desiree Ruiz-Vilchez; Rafaela Ortega-Castro; Pilar Font; Clementina Lopez-Medina; Montserrat Romero-Gomez; Carlos Rodriguez-Escalera; Jose Perez-Venegas; Mª Dolores Ruiz-Montesinos; Carmen Dominguez; Carmen Romero-Barco; Antonio Fernandez-Nebro; Natalia Mena-Vazquez; Jose Luis Marenco; Julia Uceda-Montañez; Mª Dolores Toledo-Coello; M. Angeles Aguirre; Alejandro Escudero-Contreras; Eduardo Collantes-Estevez; Chary Lopez-Pedrera

Copyright © 2021 Luque-Tévar, Perez-Sanchez, Patiño-Trives, Barbarroja, Arias de la Rosa, Abalos-Aguilera, Marin-Sanz, Ruiz-Vilchez, Ortega-Castro, Font, Lopez-Medina, Romero-Gomez, Rodriguez-Escalera, Perez-Venegas, Ruiz-Montesinos, Dominguez, Romero-Barco, Fernandez-Nebro, Mena-Vazquez, Marenco, Uceda-Montañez, Toledo-Coello, Aguirre, Escudero-Contreras, Collantes-Estevez and Lopez-Pedrera.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusions:

Our overall data suggest that: 1. RA patients undergoing anti-TNF-therapy conform distinctive clusters based on altered molecular profiles, which are directly linked to their clinical status at baseline. 2. Clinical effectiveness of anti-TNF therapy was divergent among these molecular clusters and associated with a specific modulation of the inflammatory response, the reestablishment of the altered oxidative status, the reduction of NETosis, and the reversion of related altered miRNAs. 3. The integrative analysis of the clinical and molecular profiles using machine learning allows the identification of novel signatures as potential predictors of therapeutic response to TNFi therapy.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

This prospective multicenter study developed an integrative clinical and molecular longitudinal study in Rheumatoid Arthritis (RA) patients to explore changes in serologic parameters following anti-TNF therapy (TNF inhibitors, TNFi) and built on machine-learning algorithms aimed at the prediction of TNFi response, based on clinical and molecular profiles of RA patients.

Source: Background:

Abstract: What methods does the paper describe?

A total of 104 RA patients from two independent cohorts undergoing TNFi and 29 healthy donors (HD) were enrolled for the discovery and validation of prediction biomarkers. Serum samples were obtained at baseline and 6 months after treatment, and therapeutic efficacy was evaluated. Serum inflammatory profile, oxidative stress markers and NETosis-derived bioproducts were quantified and miRNomes were recognized by next-generation sequencing. Then, clinical and molecular changes induced by TNFi were delineated. Clinical and molecular signatures predictors of clinical response were assessed with supervised machine learning methods, using regularized logistic regressions.

Source: Methods:

Abstract: Results

Altered inflammatory, oxidative and NETosis-derived biomolecules were found in RA patients vs. HD, closely interconnected and associated with specific miRNA profiles. This altered molecular profile allowed the unsupervised division of three clusters of RA patients, showing distinctive clinical phenotypes, further linked to the TNFi effectiveness. Moreover, TNFi treatment reversed the molecular alterations in parallel to the clinical outcome. Machine-learning algorithms in the discovery cohort identified both, clinical and molecular signatures as potential predictors of response to TNFi treatment with high accuracy, which was further increased when both features were integrated in a mixed model (AUC: 0.91). These results were confirmed in the validation cohort.

Source: Results:

Abstract: Conclusions

Our overall data suggest that: 1. RA patients undergoing anti-TNF-therapy conform distinctive clusters based on altered molecular profiles, which are directly linked to their clinical status at baseline. 2. Clinical effectiveness of anti-TNF therapy was divergent among these molecular clusters and associated with a specific modulation of the inflammatory response, the reestablishment of the altered oxidative status, the reduction of NETosis, and the reversion of related altered miRNAs. 3. The integrative analysis of the clinical and molecular profiles using machine learning allows the identification of novel signatures as potential predictors of therapeutic response to TNFi therapy.

Source: Conclusions:
Authors’ abstract

Background:

This prospective multicenter study developed an integrative clinical and molecular longitudinal study in Rheumatoid Arthritis (RA) patients to explore changes in serologic parameters following anti-TNF therapy (TNF inhibitors, TNFi) and built on machine-learning algorithms aimed at the prediction of TNFi response, based on clinical and molecular profiles of RA patients.

Methods:

A total of 104 RA patients from two independent cohorts undergoing TNFi and 29 healthy donors (HD) were enrolled for the discovery and validation of prediction biomarkers. Serum samples were obtained at baseline and 6 months after treatment, and therapeutic efficacy was evaluated. Serum inflammatory profile, oxidative stress markers and NETosis-derived bioproducts were quantified and miRNomes were recognized by next-generation sequencing. Then, clinical and molecular changes induced by TNFi were delineated. Clinical and molecular signatures predictors of clinical response were assessed with supervised machine learning methods, using regularized logistic regressions.

Results:

Altered inflammatory, oxidative and NETosis-derived biomolecules were found in RA patients vs. HD, closely interconnected and associated with specific miRNA profiles. This altered molecular profile allowed the unsupervised division of three clusters of RA patients, showing distinctive clinical phenotypes, further linked to the TNFi effectiveness. Moreover, TNFi treatment reversed the molecular alterations in parallel to the clinical outcome. Machine-learning algorithms in the discovery cohort identified both, clinical and molecular signatures as potential predictors of response to TNFi treatment with high accuracy, which was further increased when both features were integrated in a mixed model (AUC: 0.91). These results were confirmed in the validation cohort.

Conclusions:

Our overall data suggest that: 1. RA patients undergoing anti-TNF-therapy conform distinctive clusters based on altered molecular profiles, which are directly linked to their clinical status at baseline. 2. Clinical effectiveness of anti-TNF therapy was divergent among these molecular clusters and associated with a specific modulation of the inflammatory response, the reestablishment of the altered oxidative status, the reduction of NETosis, and the reversion of related altered miRNAs. 3. The integrative analysis of the clinical and molecular profiles using machine learning allows the identification of novel signatures as potential predictors of therapeutic response to TNFi therapy.

Publication and source details

Original title: Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis

Maria Luque-Tévar; Carlos Perez-Sanchez; Alejandra Mª Patiño-Trives; Nuria Barbarroja; Ivan Arias de la Rosa; Mª Carmen Abalos-Aguilera; Juan Antonio Marin-Sanz; Desiree Ruiz-Vilchez; Rafaela Ortega-Castro; Pilar Font; Clementina Lopez-Medina; Montserrat Romero-Gomez; Carlos Rodriguez-Escalera; Jose Perez-Venegas; Mª Dolores Ruiz-Montesinos; Carmen Dominguez; Carmen Romero-Barco; Antonio Fernandez-Nebro; Natalia Mena-Vazquez; Jose Luis Marenco; Julia Uceda-Montañez; Mª Dolores Toledo-Coello; M. Angeles Aguirre; Alejandro Escudero-Contreras; Eduardo Collantes-Estevez; Chary Lopez-Pedrera

Frontiers in Immunology · 2021

Edited by: Philippe Saas, INSERM U1098 Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, France

Reviewed by: Yves-Marie Pers, INSERM U1183 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice Et Immunothérapies, France; Marzena Ciechomska, National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

*Correspondence: Chary Lopez-Pedrera rosario.lopez.exts@juntadeandalucia.es

This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology

†These authors share first authorship

‡These authors share last authorship

Copyright © 2021 Luque-Tévar, Perez-Sanchez, Patiño-Trives, Barbarroja, Arias de la Rosa, Abalos-Aguilera, Marin-Sanz, Ruiz-Vilchez, Ortega-Castro, Font, Lopez-Medina, Romero-Gomez, Rodriguez-Escalera, Perez-Venegas, Ruiz-Montesinos, Dominguez, Romero-Barco, Fernandez-Nebro, Mena-Vazquez, Marenco, Uceda-Montañez, Toledo-Coello, Aguirre, Escudero-Contreras, Collantes-Estevez and Lopez-Pedrera.2021Luque-Tévar, Perez-Sanchez, Patiño-Trives, Barbarroja, Arias de la Rosa, Abalos-Aguilera, Marin-Sanz, Ruiz-Vilchez, Ortega-Castro, Font, Lopez-Medina, Romero-Gomez, Rodriguez-Escalera, Perez-Venegas, Ruiz-Montesinos, Dominguez, Romero-Barco, Fernandez-Nebro, Mena-Vazquez, Marenco, Uceda-Montañez, Toledo-Coello, Aguirre, Escudero-Contreras, Collantes-Estevez and Lopez-Pedrerahttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Instituto de Salud Carlos III10.13039/501100004587PI18/00837RD16/0012/0015Servicio Andaluz de Salud10.13039/501100018780PI-0285-2017

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:13:28.494197+00:00

DOI: 10.3389/fimmu.2021.631662 · PMC8022208